-->

Tag: non-surgical NF1 tumor treatment

Home / non-surgical NF1 tumor treatment

Categories

Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection

On February 11, 2025, the Food and Drug Administration sanctioned mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients aged 2 years and older di...
non-surgical-nf1-tumor-treatment

Scan the code